The North America Herpes Simplex Virus Treatment Market should witness market growth of 1.8% CAGR during the forecast period (2022-2028).
HSV-1 is mostly spread through contact with surfaces in or near the mouth, saliva, or sores that have the virus present. Less frequently, HSV-1 can spread from the mouth to the genital region and produce genital herpes. The danger of transmission is most serious when there are open sores, whether on the skin or in the mouth. HSV-1-positive individuals are not in danger of reinfection, but such individuals are still at risk of contracting HSV-2. HSV-2 is primarily spread during intercourse by contact with the anal or genital surfaces, skin, lesions, or fluids of an infected person.
HSV-2 can spread even if the skin seems normal and frequently does so without causing any symptoms. Neonatal herpes (HSV-1 & HSV-2) can, in extremely rare cases, be passed from mother to infant during birth. Currently, several herpes simplex virus control treatments are available in the market, like vaccines, pills, etc. A vaccine called SB208141 that GSK created has just finished Phase III of clinical trials.
Research and development efforts to create and offer competent and effective preventive solutions as vaccine candidates are additionally propelling the market's expansion. Also, since there is no licensed vaccine or treatment for herpes on the market, there is a greater need to produce and manufacture novel products.
Due to the rising frequency of herpes simplex virus infections, the demand for its treatment is rising in North America. Analytic Characterization of the Herpes Simplex Virus Type 2 Epidemic in the United States, 1950-2050, published in the Open Forum Infectious Diseases Journal in April 2021, claimedthat over a century, the epidemic had changed significantly, having the greatest impact on people between the ages of 15 and 34. Moreover,in addition to the 47 million HSVillnesses that affectedmany people in 2020, there will be a high incidence during the following three decades, with more than 600,000 new infections arising each year. Therefore, the region's market is anticipated to develop due to the rising number of HSVinfections.
The US market dominated the North America Herpes Simplex Virus Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $532.3 Million by 2028. The Canada market is poised to grow at a CAGR of 3.8% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 3.5% during (2022-2028).
Based on Drug Type, the market is segmented into Valacyclovir, Acyclovir, and Famciclovir. Based on Type, the market is segmented into Herpes simplex virus-1 Infection, and Herpes simplex virus-2 Infection. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Pfizer, Inc., Amneal Pharmaceuticals, Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., Glenmark Pharmaceuticals Limited, Fresenius SE & Co. KGaA, Novartis AG, Viatris, Inc., and Emcure Pharmaceuticals Limited.
HSV-1 is mostly spread through contact with surfaces in or near the mouth, saliva, or sores that have the virus present. Less frequently, HSV-1 can spread from the mouth to the genital region and produce genital herpes. The danger of transmission is most serious when there are open sores, whether on the skin or in the mouth. HSV-1-positive individuals are not in danger of reinfection, but such individuals are still at risk of contracting HSV-2. HSV-2 is primarily spread during intercourse by contact with the anal or genital surfaces, skin, lesions, or fluids of an infected person.
HSV-2 can spread even if the skin seems normal and frequently does so without causing any symptoms. Neonatal herpes (HSV-1 & HSV-2) can, in extremely rare cases, be passed from mother to infant during birth. Currently, several herpes simplex virus control treatments are available in the market, like vaccines, pills, etc. A vaccine called SB208141 that GSK created has just finished Phase III of clinical trials.
Research and development efforts to create and offer competent and effective preventive solutions as vaccine candidates are additionally propelling the market's expansion. Also, since there is no licensed vaccine or treatment for herpes on the market, there is a greater need to produce and manufacture novel products.
Due to the rising frequency of herpes simplex virus infections, the demand for its treatment is rising in North America. Analytic Characterization of the Herpes Simplex Virus Type 2 Epidemic in the United States, 1950-2050, published in the Open Forum Infectious Diseases Journal in April 2021, claimedthat over a century, the epidemic had changed significantly, having the greatest impact on people between the ages of 15 and 34. Moreover,in addition to the 47 million HSVillnesses that affectedmany people in 2020, there will be a high incidence during the following three decades, with more than 600,000 new infections arising each year. Therefore, the region's market is anticipated to develop due to the rising number of HSVinfections.
The US market dominated the North America Herpes Simplex Virus Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $532.3 Million by 2028. The Canada market is poised to grow at a CAGR of 3.8% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 3.5% during (2022-2028).
Based on Drug Type, the market is segmented into Valacyclovir, Acyclovir, and Famciclovir. Based on Type, the market is segmented into Herpes simplex virus-1 Infection, and Herpes simplex virus-2 Infection. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Pfizer, Inc., Amneal Pharmaceuticals, Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., Glenmark Pharmaceuticals Limited, Fresenius SE & Co. KGaA, Novartis AG, Viatris, Inc., and Emcure Pharmaceuticals Limited.
Scope of the Study
By Drug Type
- Valacyclovir
- Acyclovir
- Famciclovir
By Type
- Herpes simplex virus-1 Infection
- Herpes simplex virus-2 Infection
By Distribution Channel
- Drug Store & Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Pfizer, Inc.
- Amneal Pharmaceuticals, Inc.
- GlaxoSmithKline PLC
- Teva Pharmaceuticals Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Fresenius SE & Co. KGaA
- Novartis AG
- Viatris, Inc.
- Emcure Pharmaceuticals Limited
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. North America Herpes Simplex Virus Treatment Market by Drug Type
Chapter 4. North America Herpes Simplex Virus Treatment Market by Type
Chapter 5. North America Herpes Simplex Virus Treatment Market by Distribution Channel
Chapter 6. North America Herpes Simplex Virus Treatment Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Pfizer, Inc.
- Amneal Pharmaceuticals, Inc.
- GlaxoSmithKline PLC
- Teva Pharmaceuticals Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Fresenius SE & Co. KGaA
- Novartis AG
- Viatris, Inc.
- Emcure Pharmaceuticals Limited
Methodology
LOADING...
Related Reports
From
From
Herpes Simplex Virus Treatment Global Market Report 2024
- Report
- 200 Pages
- Global
From
From
Herpes Simplex Virus Treatment Market - Forecasts from 2024 to 2029
- Report
- 140 Pages
- Global
From
About the Herpes Drug Market
The Herpes Drug market is a subset of the Infectious Diseases Drugs market, which includes drugs used to treat a variety of infectious diseases. Herpes drugs are used to treat the herpes simplex virus (HSV) and its associated conditions, such as genital herpes, cold sores, and shingles. These drugs can be administered orally, topically, or intravenously, depending on the severity of the infection. Commonly prescribed herpes drugs include acyclovir, valacyclovir, and famciclovir. Herpes drugs are Read more
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
